Canadian biotech Zymeworks (TSX: ZYME) has reacquired rights for the antibody-drug conjugate (ADC) zanidatamab zovodotin, from partner BeiGene (Nasdaq: BGNE).
Zymeworks provided the update on the firms’ collaboration agreement as part of its financial results statement, with China-based BeiGene returning rights in the Asia–Pacific region.
The companies have been working together since November 2018, under the terms of a license and collaboration agreement for selected indications across multiple HER2-expressing cancers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze